Literature DB >> 838796

Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame-ionization and nitrogen-selective detection.

M S Lennard, J H Silas, A J Smith, G T Tucker.   

Abstract

Specific methods have been devised for the simultaneous determination of the guanidino-type antihypertensive agent debrisoquine and its 4-hydroxy metabolite in human urine, involving in situ derivatisation with acetylacetone, extraction of the resulting pyrimidines, and gas chromatography using a flame-ionisation detector or a nitrogen-specific detector. Using the latter, a similar procedure was also developed to measure debrisoquine in human plasma and whole blood following prior extraction at pH 13.5 with chloroform. Concentrations down to 3 ng/ml can be measured accurately using a 1.0-ml sample. The methods were applied to the analysis of samples collected after a single 20-mg oral dose of debrisoquine hemisulphate.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 838796     DOI: 10.1016/s0021-9673(00)89216-x

Source DB:  PubMed          Journal:  J Chromatogr


  56 in total

1.  Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects.

Authors:  E Spina; M Ancione; A E Di Rosa; M Meduri; A P Caputi
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Influence of debrisoquine oxidation phenotype on exercise tolerance and subjective fatigue after metoprolol and atenolol in healthy subjects.

Authors:  R V Lewis; L E Ramsay; P R Jackson; W W Yeo; M S Lennard; G T Tucker
Journal:  Br J Clin Pharmacol       Date:  1991-04       Impact factor: 4.335

3.  Lack of effect of omeprazole treatment on steady-state plasma levels of metoprolol.

Authors:  T Andersson; P Lundborg; C G Regårdh
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

4.  Pharmacogenetics and drug metabolism: an Irish perspective.

Authors:  P Holland; M Barry; J Feely
Journal:  Ir J Med Sci       Date:  1991-02       Impact factor: 1.568

5.  Oxidative polymorphism of debrisoquine in Parkinson's disease.

Authors:  J Benitez; J M Ladero; F J Jimenez-Jimenez; C Martinez; A M Puerto; M J Valdivielso; A Llerena; J Cobaleda; J J Muñoz
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-04       Impact factor: 10.154

6.  Polymorphic metabolism of metoprolol: clinical studies.

Authors:  J H Silas; J C McGourty; M S Lennard; G T Tucker; H F Woods
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

7.  Pharmacokinetic properties and bioavailability of methimazole.

Authors:  R Jansson; B Lindström; P A Dahlberg
Journal:  Clin Pharmacokinet       Date:  1985 Sep-Oct       Impact factor: 6.447

8.  Identification of propafenone metaboliser phenotype from plasma and urine excretion data.

Authors:  R Latini; M Belloni; R Bernasconi; E Cappiello; P Giani; M Landolina; D Leopaldi; J M Castel
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

9.  Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism.

Authors:  K Brøsen; R Klysner; L F Gram; S V Otton; P Bech; L Bertilsson
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

10.  Dissociation of biochemical and hypotensive effects of debrisoquine in hypertensive patients.

Authors:  J H Silas; J Jones; G T Tucker; M M Townshend; C A Phillips; A J Smith
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.